Characterization of the epigenetic regulator LSD1 as a druggable dependency in treatment resistant melanoma
Author
Silkworth, Whitney Camp
Metadata
Show full item recordCitation
Silkworth, Whitney Camp. 2018. Characterization of the epigenetic regulator LSD1 as a druggable dependency in treatment resistant melanoma. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences.Abstract
Melanoma, a deadly form of skin cancer, arises from the malignant transformation of melanocytes. Advances in targeted and immune therapies for melanoma provide clinical benefit but are ultimately met with resistance and inadequate clinical response. Previous analyses of patient biopsies and cell lines revealed that both acquired and intrinsic resistance to these therapies are associated with an undifferentiated cell state characterized by low levels of microphthalmia-associated transcription factor (MITF), the master regulator of melanocyte development, and high levels of AXL receptor tyrosine kinase (AXL).In this thesis, I characterize the epigenetic regulator lysine-specific demethylase-1 (LSD1) as a targetable vulnerability in treatment resistant MITF-low/AXL-high melanoma. I extensively validate the dependence of MITF-low melanoma cells on LSD1 using multiple independent genetic and pharmacologic approaches. Furthermore, the toxicity of LSD1 loss is shown to be specific to MITF-low, but not MITF-high, melanoma cells.
To identify a mechanism by which LSD1 mediates survival of MITF-low melanoma cells, we performed genome-wide transcriptome and chromatin analyses and found that LSD1 represses N-myc Downstream-Regulated Gene-1 (NDRG1) via demethylation of dimethyl histone 3 lysine 4 (H3K4me2). We confirmed LSD1 occupancy of the NDRG1 promoter and show that NDRG1 is essential for LSD1 inhibition-mediated suppression of MITF-low melanoma growth, as loss of NDRG1 abrogates the effects of LSD1 inhibition.
Using xenografts bearing MITF-low melanoma tumors, I demonstrate that LSD1 inhibition reduces tumor burden and correlates with NDRG1 RNA induction, which I show serves as a biomarker for on-target LSD1 inhibition. I also assessed the anti- tumor effects of LSD1 inhibitors in rational combinations with targeted and immune therapies both in vitro and in vivo.
Finally, we demonstrate that the dependency on LSD1 in melanoma cells expressing low levels of MITF and high levels of AXL extends to pancreatic adenocarcinomas characterized by a transcriptional profile defined by high-AXL expression. These findings reveal mechanistic insights and identify a therapeutically vulnerable epigenetic state in poorly differentiated, therapy-resistant cancers, including subsets of melanoma, pancreatic cancer, and possibly other cancer types. LSD1 inhibitors can potentially be valuable additions to the currently limited treatment options for these patients.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41121249
Collections
- FAS Theses and Dissertations [5848]
Contact administrator regarding this item (to report mistakes or request changes)